Bibliography:-

1. Bernard Van Eerdenbrugh, Guy Van den Mooter ,Patrick Augustijns (2008) Top-down production of drug nanocrystals: Nanosuspension stabilization,miniaturization and transformation into solid products International Journal of Pharmaceutics, 364 ,64–75.
2. Bloomston M, Bhardwaj A, Ellison EC, Frankel WL.2006. Epidermal growth factor receptor expression in pancreatic carcinoma using tissue microarray technique. Dig Surg.23:74–79
3. Benekli M, Yildiz R, Uner A.2007. Gemcitabine plus capecitabine combination in metastatic breast cancer patients previously treated with anthracyclines and taxanes. Oncology. 72: 308-313.
4. Dengning Xiaa, Peng Quan,Hongze Piaoa, Hongyu Piao,Shaoping SunYongmei Yin,Fude Cui, (2010) Preparation of stable nitrendipine nanosuspensions using the precipitation–ultrasonication method for enhancement of dissolution and oral bioavailability, European Journal of Pharmaceutical Sciences ,40,325–334.
5. Grau M.J., Kayser O., Muller R.H. (2000) Nanosuspensions of poorly soluble drugs reproducibility of small scale production, International Journal of Pharmaceutics ,196 ,155–157.
6. G.Maruthi G., Smith.2011. Nanoparticles – A Review Journal of Advanced Scientific Research 2011; 2(4): 12-19
7. Gabrielle Pilcer, Francis Vanderbist, Karim Amighi, (2009) Preparation and characterization of spray-dried tobramycin powders containing nanoparticles for pulmonary delivery International Journal of Pharmaceutics 365 162–169
8. Herman JM, Swartz MJ, Hsu CC, Winter J, Pawlik TM, Sugar E, Robinson R, Laheru DA, Jaffee E, Hruban RH, 2008. Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreatic oduodenectomy for ductal adenocarcinoma of the pancreas: J Clin Oncol.26:3503–3510.
9. Harivardhan L. Reddy,R Murthy.S.R. (2005)Etoposide-Loaded Nanoparticles Made from Glyceride Lipids: Formulation, Characterization, in Vitro Drug Release, and Stability Evaluation AAPS Pharm SciTech; 6 (2) E158-166.
10. Hennessy BT, Gauthier AM, Michaud LB.2005. Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M.D. Anderson Cancer Center and a review of capecitabine toxicity in the literature.Ann Oncol. 16: 1289–1296.

11. Harivardhan L. Reddy,R Murthy.S.R. (2005)Etoposide-Loaded Nanoparticles Made from Glyceride Lipids: Formulation, Characterization, in Vitro Drug Release, and Stability Evaluation AAPS Pharm SciTech; 6 (2) E158-166.
12. Hong S, Young D, Heung C2008. A phase II study of capecitabine plus gemcitabine in patients with locally advanced or metastatic pancreatic patients. Cancer Chemother Pharmacol.62 (5): 763–768.
13. Harivardhan L. Reddy,R Murthy.S.R. (2005) Etoposide-Loaded Nanoparticles Made from Glyceride Lipids: Formulation, Characterization, in Vitro Drug Release, and Stability Evaluation AAPS Pharm Sci Tech; 6 (2) E158-166.
14. Ji-Yeun Choi ,Chul Ho Park,Jonghwi Lee (2008), Effect of Polymer Molecular Weight on Nanocomminution of Poorly Soluble Drug Nanoparticles Drug Development and Industrial Pharmacy,34:1209–1218
15. Jannin, V. Musakhanian J., Marchaud D. (2008) Approaches for the development of solid and semi-solid lipid-based formulations Advanced Drug Delivery Reviews ,60 ,734–746..
16. Katy M, ShlomoM.(2009) Formation of simvastatin nanoparticles from microemulsion Nanomedicine: Nanotechnology, Biology, and Medicine. 5 ,274–281.
17. Kulke MH, Blaszkowsky LS, Ryan DP, Clark JW, Meyerhardt JA, Zhu AX, Enzinger PC, Kwak EL, Muzikansky A, Lawrence C, 2007. Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. J Clin Oncol.25:4787–4792.
18. Kalle S Sara F, Hollander,P.Urban SdeerV (2007) A formulation comparison, using a solution and different nanosuspensions of a poorly soluble compound, European Journal of Pharmaceutics and Biopharmaceutics 67, 540–547.
19. Kassem M.A., Abdel Rahmanb,A.A. Ghorab M.M., Ahmed M.B., Khalil R.M. (2007) Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs, International Journal of Pharmaceutics ,340 ,126–133.
20. Lei G Zhang,M Chen Zheng,T. Wang S. (2007)Preparation and Characterization of an Oridonin Nanosuspension for Solubility and Dissolution Velocity Enhancement, Drug Development and Industrial *Pharmacy*, 33:1332–1339.
21. Lee SC, Oh JT, Jang MH. Jang. 1999. Quantitative analysis of polyvinyl alcohol on the surface of poly (D,L-lactide-coglycolide) microparticles prepared by solvent evaporation method: effect of particle size and PVA concentration, Journal of Controlled Release, 59(2), 123-132.

22. Laheru D, Croghan G, Bukowski R, Rudek M, Messersmith W, Erlichman C, Pelley R, Jimeno A, Donehower R, Boni J, and 2008.A phase I study of ekb-569 in combination with Capecitabine in patients with advanced colorectal cancer. Clin Cancer Res.14:5602–5609.
23. Leena Peltonen,Johanna Aitt Samuli Hyvönen, Milja Karjalainen, and Jouni Hirvonen, 2004 Improved Entrapment Efficiency of Hydrophilic Drug Substance During Nanoprecipitation of Poly(l)lactide Nanoparticles AAPS PharmSciTech; 5 (1) 1-6.
24. LaF.Pini E., Angioni, G. MancM.L.Perricci,J.Sinico C. (2011) Nanocrystals as tool to improve piroxicam dissolution rate in novel orally disintegrating tablets European Journal of Pharmaceutics and Biopharmaceutics 79 ,552–558
25. Lipinski, C.A., 2002. Poor aqueous solubility – an industry wide problem in drug 770 discovery. Am. Pharm. Rev. 5, 82–85.
26. Mittal V., Patel S.2010 Development and characterization of folate targeted nanoparticles drug delivery system, International journal of pharma and biosciences, 1(2) 102-110.
27. Ouchi KF, Yanagisawa M, Sekiguchi F, Tanaka Y.2006. Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models. Cancer Chemother Pharmacol.57: 693–702.
28. Patrice Tewa-Tagne, St´ephanie Brianc¸onHatem Fessi (2007) Preparation of redispersible dry nanocapsules by means of spray-drying: Development and characterization, european journal of pharmaceutical sciences .3 0, 124–135.;.
29. Park TG,Yoo HS,2002,Polymer Preparation,Polymer Parameters,41:992-3.
30. Roy V.Gross GG.,Bane, 2008. Paclitaxel plus gemcitabine compared patients with advanced metastatic breast cancer: a phase III trial of the the European society for medical oncology.25: 1960–1966.
31. Rini BI, Weinberg V, Small EJ. 2005. A phase I trial of fixed dose rate gemcitabine and capecitabine in metastatic renal cell carcinoma. Cancer.103: 553–558.
32. Sawada N, Fujimoto-Ouchi K, Ishikawa T, 2002. Antitumor activity of combination therapy with capecitabine plus vinorelbine, and capecitabine plus gemcitabine in human tumor xenograft models. Proc Am Assoc Cancer Res .43 : (Abstr 5388).
33. Singh S.K,K.K. Srinivasan ,K. Gowthamaraja, Dhananjay S. Singare,Dev Prakash (2011) Investigation of preparation parameters of nanosuspension by top-down media milling to

improve the dissolution of poorly water-soluble glyburide, European Journal of Pharmaceutics and Biopharmaceutics, 78, 441–446.

34. Spomenka S. Hui,Y Song,Andrew K. Thomas D, Clive R, Prestidge A., (2010) An oral delivery system for indomethicin engineered from cationic lipid emulsions and silica nanoparticles, Journal of Controlled Release ,143, 367–373.
35. Suzanne M. D'Addio, Robert K. Prud'homme, (2011), Controlling drug nanoparticle formation by rapid precipitation, Advanced Drug Delivery Reviews .63, 417–426.
36. Schilsky RL, Bertucci D, Vogelzang NJ.2002. Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer. J Clin Oncol.20: 582-587.
37. Santini D, Virzı´ V, Vincenzi B.2007. A phase I trial of fixed dose rate gemcitabine plus capecitabine in metastatic cancer patients. Ann Oncol. 18: 576–580.
38. Tangri,P. Khurana S.2011 Nanoparticles – A Review International Journal of advancesin pharmaceutical research 2(7): 331-339.
39. Uner M. 2006.Preparation, characterization and physico-chemical properties of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC): their benefits as colloidal drug Carrier systems. Pharmazie 61:375-86.
40. Van Cutsem E, Verslype C, Beale P, Clarke S, Bugat R, Rakhit A, Fettner SH, Brennscheidt U, Feyereislova A, Delord JP.2008. A phase IB dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients. Ann Oncol. 19:332–339.
41. Vijaykumar Nekkanti Raviraj Pillai Vobalaboina Venkateshwarlu T Harisudhan (2009) Development and characterization of solid oral dosage form incorporating candesartan nanoparticles, *Pharmaceutical Development and Technology*,14(3): 290–298.
42. Vyas SP,Khar RK .2007. Targeted and Controlled drug delivery 1st edition, 331.
43. Wong HL, Rauth AM, Bendayan R. A 2007.New polymer-lipid hybrid nanoparticle system increases cytotoxicity of doxorubicin against multidrug-resistant human breast cancer cells. Pharm Res 23:1574-85
44. Yuancai D Wai K. N,Jun H. (2009) A continuous and highly effective static mixing process for antisolvent precipitation of nanoparticles of poorly water-soluble drugs International Journal of Pharmaceutics xxx, xxx–xxx.